ALBPS Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.…
Industry Peers
BiotechnologyKey Statistics
About Biophytis (EPA: ALBPS)
›
Biophytis (EPA: ALBPS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 0.0332 EUR on 19 November 2026, down 58.4% over 52 weeks. Its 52-week range is 0.0042 EUR to 0.1550 EUR: the price is 78.6% below the high and 690.5% above the low.
Its market capitalisation is 12.36M EUR.
Biophytis reports an operating margin of 0.0%.
Its debt exceeds its cash by 6.51M EUR. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health.